Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Tuberculosis

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 74 articles:
HTML format
Text format



Single Articles


    November 2017
  1. GARFIN C, Mantala M, Yadav R, Hanson CL, et al
    Using Patient Pathway Analysis to Design Patient-centered Referral Networks for Diagnosis and Treatment of Tuberculosis: The Case of the Philippines.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  2. HANSON C, Osberg M, Brown J, Durham G, et al
    Finding the Missing Patients With Tuberculosis: Lessons Learned From Patient-Pathway Analyses in 5 Countries.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  3. HANSON CL, Osberg M, Brown J, Durham G, et al
    Conducting Patient-Pathway Analysis to Inform Programming of Tuberculosis Services: Methods.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  4. MASINI E, Hanson C, Ogoro J, Brown J, et al
    Using Patient-Pathway Analysis to Inform a Differentiated Program Response to Tuberculosis: The Case of Kenya.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  5. FATIMA R, Haq MU, Yaqoob A, Mahmood N, et al
    Delivering Patient-Centered Care in a Fragile State: Using Patient-Pathway Analysis to Understand Tuberculosis-Related Care Seeking in Pakistan.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  6. SURYA A, Setyaningsih B, Suryani Nasution H, Gita Parwati C, et al
    Quality Tuberculosis Care in Indonesia: Using Patient Pathway Analysis to Optimize Public-Private Collaboration.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  7. FEKADU L, Hanson C, Osberg M, Makayova J, et al
    Increasing Access to Tuberculosis Services in Ethiopia: Findings From a Patient-Pathway Analysis.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  8. SISMANIDIS C, Shete PB, Lienhardt C, Floyd K, et al
    Harnessing the Power of Data to Guide Local Action and End Tuberculosis.
    J Infect Dis. 2017;216.
    PubMed     Text format    


  9. REID MJA, Goosby E
    Patient-Centered Tuberculosis Programs Are Necessary to End the Epidemic.
    J Infect Dis. 2017;216.
    PubMed     Text format    


  10. CHIN DP, Hanson CL
    Finding the Missing Tuberculosis Patients.
    J Infect Dis. 2017;216.
    PubMed     Text format    


  11. NAIDOO P, Theron G, Rangaka MX, Chihota VN, et al
    The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  12. CHURCHYARD G, Kim P, Shah NS, Rustomjee R, et al
    What We Know About Tuberculosis Transmission: An Overview.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  13. TURNER RD, Chiu C, Churchyard GJ, Esmail H, et al
    Tuberculosis Infectiousness and Host Susceptibility.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  14. MATHEMA B, Andrews JR, Cohen T, Borgdorff MW, et al
    Drivers of Tuberculosis Transmission.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  15. AULD SC, Kasmar AG, Dowdy DW, Mathema B, et al
    Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There?
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  16. DOWDY DW, Grant AD, Dheda K, Nardell E, et al
    Designing and Evaluating Interventions to Halt the Transmission of Tuberculosis.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  17. SHAH NS, Kim P, Kana BD, Rustomjee R, et al
    Getting to Zero New Tuberculosis Infections: Insights From the National Institutes of Health/US Centers for Disease Control and Prevention/Bill & Melinda Gates Foundation Workshop on Research Needs for Halting Tuberculosis Transmission.
    J Infect Dis. 2017;216.
    PubMed     Text format    


  18. SALVATORE PP, Proano A, Kendall EA, Gilman RH, et al
    Linking individual natural history to population outcomes in tuberculosis.
    J Infect Dis. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2017
  19. BUNJUN R, Riou C, Soares AP, Thawer N, et al
    Effect of HIV on the frequency and number of Mycobacterium tuberculosis-specific CD4+ T cells in blood and the airways in latent tuberculosis infection.
    J Infect Dis. 2017 Oct 5. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  20. ROCKWOOD N, Sirgel F, Streicher E, Warren R, et al
    Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence.
    J Infect Dis. 2017;216:632-640.
    PubMed     Text format     Abstract available


    August 2017
  21. SINGH V, Prakhar P, Rajmani RS, Mahadik K, et al
    Histone Methyltransferase SET8 Epigenetically Reprograms Host Immune Responses to Assist Mycobacterial Survival.
    J Infect Dis. 2017;216:477-488.
    PubMed     Text format     Abstract available


    June 2017
  22. FOLKVARDSEN DB, Norman A, Andersen AB, Rasmussen EM, et al
    Genomic epidemiology of a major Mycobacterium tuberculosis outbreak: Retrospective cohort study in a low incidence setting using sparse time-series sampling.
    J Infect Dis. 2017 Jun 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. GUPTA S, Cheung L, Pokkali S, Winglee K, et al
    Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis.
    J Infect Dis. 2017;215:1883-1887.
    PubMed     Text format     Abstract available


    May 2017
  24. YAO Y, Lai R, Afkhami S, Haddadi S, et al
    A novel virus-vectored respiratory mucosal vaccine enhances anti-tuberculosis immunity in a humanized model system.
    J Infect Dis. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. ANTHONY RM
    Sputum microscopy and tuberculosis infectiousness.
    J Infect Dis. 2017 May 16. doi: 10.1093.
    PubMed     Text format    


  26. DATTA S, Sherman JM, Tovar MA, Bravard MA, et al
    Sputum microscopy with fluorescein diacetate predicts tuberculosis infectiousness.
    J Infect Dis. 2017 May 16. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2017
  27. THUONG NTT, Heemskerk D, Tram TTB, Thao LTP, et al
    Leukotriene A4 Hydrolase Genotype and HIV Infection Influence Intracerebral Inflammation and Survival From Tuberculous Meningitis.
    J Infect Dis. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  28. OEHLERS SH, Cronan MR, Beerman RW, Johnson MG, et al
    Infection-Induced Vascular Permeability Aids Mycobacterial Growth.
    J Infect Dis. 2017;215:813-817.
    PubMed     Text format     Abstract available


    February 2017
  29. HALLIDAY A, Whitworth H, Hermagild Kottoor S, Niazi U, et al
    Stratification of latent tuberculosis infection by cellular immune profiling.
    J Infect Dis. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. SHEN H, Gu J, Xiao H, Liang S, et al
    Selective Destruction of Interleukin 23-Induced Expansion of a Major Antigen-Specific gammadelta T-Cell Subset in Patients With Tuberculosis.
    J Infect Dis. 2017;215:420-430.
    PubMed     Text format     Abstract available


    January 2017
  31. CLARK S, Lanni F, Marinova D, Rayner E, et al
    Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis.
    J Infect Dis. 2017 Jan 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. JANSSEN S, Schutz C, Ward AM, Huson MA, et al
    Hemostatic Changes Associated With Increased Mortality Rates in Hospitalized Patients With HIV-Associated Tuberculosis: A Prospective Cohort Study.
    J Infect Dis. 2017;215:247-258.
    PubMed     Text format     Abstract available


    December 2016
  33. MARAIS S, Lai RP, Wilkinson KA, Meintjes G, et al
    Inflammasome activation underlies central nervous system deterioration in HIV-associated tuberculosis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    October 2016
  34. JEYANATHAN M, Damjanovic D, Yao Y, Bramson J, et al
    Induction of an immune protective T cell repertoire with diverse genetic coverage by a novel viral-vectored tuberculosis vaccine in man.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    September 2016
  35. MARTINEZ N, Ketheesan N, West K, Vallerskog T, et al
    Impaired Recognition of Mycobacterium tuberculosis by Alveolar Macrophages from Diabetic Mice.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  36. SINGH DK, Dwivedi VP, Ranganathan A, Bishai WR, et al
    Blockade of the Kv1.3 K+ channel enhances BCG vaccine efficacy by expanding central memory T lymphocytes.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  37. SCHLUGER NW
    Host-pathogen interactions in tuberculosis: the evolving story.
    J Infect Dis. 2016.
    PubMed     Text format    


  38. WALTER ND, de Jong BC, Garcia BJ, Dolganov GM, et al
    Adaptation of M. tuberculosis to impaired host immunity in HIV-infected patients.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  39. CHEN L, Zhang J, Zhang H
    Heteroresistance of Mycobacterium tuberculosis strains may be associated more strongly with poor treatment outcomes than within-host heterogeneity of M. tuberculosis infection.
    J Infect Dis. 2016.
    PubMed     Text format    


  40. HORNE DJ, Graustein AD, Shah JA, Peterson G, et al
    Human ULK1 Variation and Susceptibility to Mycobacterium tuberculosis Infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  41. DINARDO AR, Mace EM, Lesteberg K, Cirillo JD, et al
    Schistosome Soluble Egg Antigen Decreases Mycobacterium tuberculosis-Specific CD4+ T-Cell Effector Function With Concomitant Arrest of Macrophage Phago-Lysosome Maturation.
    J Infect Dis. 2016;214:479-88.
    PubMed     Text format     Abstract available


  42. AHSAN F, Moura-Alves P, Guhlich-Bornhof U, Klemm M, et al
    Role of Interleukin 36gamma in Host Defense Against Tuberculosis.
    J Infect Dis. 2016;214:464-74.
    PubMed     Text format     Abstract available


    July 2016
  43. DIEDRICH CR, O'Hern J, Gutierrez MG, Allie N, et al
    Relationship between HIV-1 co-infection, IL-10, and M. tuberculosis in human lymph node granulomas.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  44. YANG HJ, Kong Y, Cheng Y, Janagama H, et al
    Real-Time Imaging of Mycobacterium tuberculosis Using a Novel Near-Infrared Fluorescent Substrate.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    May 2016
  45. SCRIBA TJ, Kaufmann SH, Lambert PH, Sanicas M, et al
    Vaccination against tuberculosis with whole cell mycobacterial vaccines.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  46. SHEPELKOVA G, Evstifeev V, Majorov K, Bocharova I, et al
    Therapeutic effect of recombinant mutated IL-11 in the mouse model of tuberculosis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    April 2016
  47. PRADOS-ROSALES R, Carreno LJ, Weinrick B, Batista-Gonzalez A, et al
    The Type of Growth Medium Affects the Presence of a Mycobacterial Capsule and Is Associated With Differences in Protective Efficacy of BCG Vaccination Against Mycobacterium tuberculosis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  48. JOLOBA M, Mwangi C, Alexander H, Nadunga D, et al
    Strengthening the Tuberculosis Specimen Referral Network in Uganda: The Role of Public-Private Partnerships.
    J Infect Dis. 2016;213 Suppl 2:S41-6.
    PubMed     Text format     Abstract available


  49. JABOT-HANIN F, Cobat A, Feinberg J, Grange G, et al
    Major Loci on Chromosomes 8q and 3q Control Interferon gamma Production Triggered by Bacillus Calmette-Guerin and 6-kDa Early Secretory Antigen Target, Respectively, in Various Populations.
    J Infect Dis. 2016;213:1173-9.
    PubMed     Text format     Abstract available


    March 2016
  50. MINHINNICK A, Harris S, Wilkie M, Peter J, et al
    Optimization of a Human Bacille Calmette-Guerin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity.
    J Infect Dis. 2016;213:824-30.
    PubMed     Text format     Abstract available


    January 2016
  51. COHEN T, Chindelevitch L, Misra R, Kempner ME, et al
    Within-host heterogeneity of M. tuberculosis infection is associated with poor early treatment response: a prospective cohort study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    November 2015
  52. BOILLAT-BLANCO N, Ramaiya KL, Mganga M, Minja LT, et al
    Transient Hyperglycemia in Patients with Tuberculosis in Tanzania: Implications for Diabetes Screening Algorithms.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  53. ELLIOTT TO, Owolabi O, Donkor S, Kampmann B, et al
    Dysregulation of Apoptosis Is a Risk Factor for Tuberculosis Disease Progression.
    J Infect Dis. 2015;212:1469-79.
    PubMed     Text format     Abstract available


    October 2015
  54. AGUILO N, Alvarez-Arguedas S, Uranga S, Marinova D, et al
    Pulmonary but not subcutaneous vaccination confers protection to TB susceptible mice by an IL17-dependent mechanism.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  55. KUMAR NP, Moideen K, George PJ, Dolla C, et al
    Impaired cytokine but enhanced cytotoxic marker expression in Mycobacterium tuberculosis - induced CD8+ T cells in Type 2 diabetic individuals with latent tuberculosis.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    September 2015
  56. KUBLER A, Larsson C, Luna B, Andrade BB, et al
    Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  57. KASPROWICZ VO, Cheng TY, Ndung'u T, Sunpath H, et al
    HIV disrupts human T cells that target mycobacterial glycolipids.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  58. CLIFF JM, Cho JE, Lee JS, Ronacher K, et al
    Excessive Cytolytic Responses Predict Tuberculosis Relapse After Apparently Successful Treatment.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    July 2015
  59. ZELNER JL, Murray MB, Becerra MC, Galea J, et al
    Identifying hotspots of multidrug resistant tuberculosis transmission using spatial and molecular genetic data.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  60. ARMITAGE AE, Moran E
    HIV-associated tuberculosis: does the iron-regulatory hormone hepcidin connect anemia with poor prognosis?
    J Infect Dis. 2015.
    PubMed     Text format    


  61. KERKHOFF AD, Meintjes G, Burton R, Vogt M, et al
    Relationship between blood concentrations of hepcidin and anaemia severity, mycobacterial burden and mortality in patients with HIV-associated tuberculosis.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  62. PASIPANODYA J, Srivastava S, Gumbo T
    Fatal Lure of Look-Back Studies in Explaining Pharmacological Events Such as Acquired Drug Resistance in Patients With Multidrug-Resistant Tuberculosis.
    J Infect Dis. 2015;212:166-7.
    PubMed     Text format    


    June 2015
  63. SALVATORE PP, Becerra MC, Zur Wiesch PA, Hinkley T, et al
    Fitness Costs of Drug-resistance Mutations in Multidrug Resistant M. tuberculosis: A Household-based Case-control Study.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  64. NUERMBERGER E, Hanna D
    Assessing the landscape of tools and approaches for novel tuberculosis regimen development.
    J Infect Dis. 2015;211 Suppl 3:S81-2.
    PubMed     Text format    


  65. MCILLERON H, Abdel-Rahman S, Dave JA, Blockman M, et al
    Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research.
    J Infect Dis. 2015;211 Suppl 3:S115-25.
    PubMed     Text format     Abstract available


  66. GUMBO T, Angulo-Barturen I, Ferrer-Bazaga S
    Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.
    J Infect Dis. 2015;211 Suppl 3:S96-S106.
    PubMed     Text format     Abstract available


  67. GUMBO T, Lenaerts AJ, Hanna D, Romero K, et al
    Nonclinical models for antituberculosis drug development: a landscape analysis.
    J Infect Dis. 2015;211 Suppl 3:S83-95.
    PubMed     Text format     Abstract available


  68. SAHASRABUDHE V, Zhu T, Vaz A, Tse S, et al
    Drug metabolism and drug interactions: potential application to antituberculosis drugs.
    J Infect Dis. 2015;211 Suppl 3:S107-14.
    PubMed     Text format     Abstract available


  69. AICHELBURG MC
    Reply to Schepisi et al.
    J Infect Dis. 2015;211:1854.
    PubMed     Text format    


    May 2015
  70. PAN SJ, Tapley A, Adamson J, Little T, et al
    Biomarkers for tuberculosis based on secreted, species-specific, bacterial small molecules.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    April 2015
  71. DENKINGER CM, Dolinger D, Schito M, Wells W, et al
    Target product profile of a molecular drug-susceptibility test for use in microscopy centers.
    J Infect Dis. 2015;211 Suppl 2:S39-49.
    PubMed     Text format     Abstract available


    January 2015
  72. SANE SCHEPISI M, Parracino MP, Mammone A, Bellagamba R, et al
    Effect of immune status on serial QuantiFERON-TB Gold In-Tube LTBI screening in persons with HIV in a low TB incidence country.
    J Infect Dis. 2015.
    PubMed     Text format    


    December 2014
  73. SAIGA H, Nieuwenhuizen N, Gengenbacher M, Koehler AB, et al
    The recombinant BCG DeltaureC::hly vaccine targets the AIM2 inflammasome to induce autophagy and inflammation.
    J Infect Dis. 2014.
    PubMed     Text format     Abstract available


    November 2014
  74. MIDDELKOOP K, Mathema B, Whitelaw A, Bekker LG, et al
    Reply to Yates et al.
    J Infect Dis. 2014.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: